These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26536315)

  • 41. Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study.
    Camlin CS; Koss CA; Getahun M; Owino L; Itiakorit H; Akatukwasa C; Maeri I; Bakanoma R; Onyango A; Atwine F; Ayieko J; Kabami J; Mwangwa F; Atukunda M; Owaraganise A; Kwarisiima D; Sang N; Bukusi EA; Kamya MR; Petersen ML; Cohen CR; Charlebois ED; Havlir DV
    AIDS Behav; 2020 Jul; 24(7):2149-2162. PubMed ID: 31955361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand.
    Tangmunkongvorakul A; Chariyalertsak S; Amico KR; Saokhieo P; Wannalak V; Sangangamsakun T; Goicochea P; Grant R
    AIDS Care; 2013 Aug; 25(8):961-7. PubMed ID: 23252473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Access to HIV Pre-exposure Prophylaxis in Practice Settings: a Qualitative Study of Sexual and Gender Minority Adults' Perspectives.
    Sun CJ; Anderson KM; Bangsberg D; Toevs K; Morrison D; Wells C; Clark P; Nicolaidis C
    J Gen Intern Med; 2019 Apr; 34(4):535-543. PubMed ID: 30719647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
    Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
    Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Invited commentary: every good randomization deserves observation.
    Westreich D; Edwards JK
    Am J Epidemiol; 2015 Nov; 182(10):857-60. PubMed ID: 26487342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
    Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
    Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.
    Sivay MV; Li M; Piwowar-Manning E; Zhang Y; Hudelson SE; Marzinke MA; Amico RK; Redd A; Hendrix CW; Anderson PL; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant R; Eshleman SH;
    J Acquir Immune Defic Syndr; 2017 Jul; 75(3):271-279. PubMed ID: 28328548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.
    Poteat T; Malik M; van der Merwe LLA; Cloete A; Adams D; Nonyane BAS; Wirtz AL
    Lancet HIV; 2020 Dec; 7(12):e825-e834. PubMed ID: 32622370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
    Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.
    Dolling DI; Desai M; McOwan A; Gilson R; Clarke A; Fisher M; Schembri G; Sullivan AK; Mackie N; Reeves I; Portman M; Saunders J; Fox J; Bayley J; Brady M; Bowman C; Lacey CJ; Taylor S; White D; Antonucci S; Gafos M; McCormack S; Gill ON; Dunn DT; Nardone A;
    Trials; 2016 Mar; 17():163. PubMed ID: 27013513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
    Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
    J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
    Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
    J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Willingness to Take PrEP and Potential for Risk Compensation Among Highly Sexually Active Gay and Bisexual Men.
    Grov C; Whitfield TH; Rendina HJ; Ventuneac A; Parsons JT
    AIDS Behav; 2015 Dec; 19(12):2234-44. PubMed ID: 25735243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
    J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake.
    Pathela P; Jamison K; Blank S; Daskalakis D; Hedberg T; Borges C
    J Acquir Immune Defic Syndr; 2020 Apr; 83(4):357-364. PubMed ID: 31904700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.